-
Sexual Dysfunction in Women N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Patrick G. O’Malley, Susan R. Davis From the Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, and the Department of Endocrinology and Diabetes, Alfred Health — both in Melbourne, VIC, Australia.
Sexual dysfunction in women impairs quality of life and is determined by multiple factors. Treatment includes lifestyle modification, counseling and psychosexual therapies, and pharmacotherapy.
-
Acute Epiploic Appendagitis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Shee Yen Tay Far Eastern Memorial Hospital, New Taipei City, Taiwan
A woman presented with dull, intermittent lower abdominal pain on the left side. CT of the abdomen showed an ovoid lesion adjacent to the descending colon that had ring enhancement and the density ...
-
Why Was the Azithromycin “for Life” Trial Necessary? N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Kathryn Maitland, and A. Sarah Walker From the Department of Infectious Disease and Institute of Global Health and Innovation, Division of Medicine, Imperial College (K.M.), and the Medical Research Council Clinical Trials Unit, University College London (A.S.W.) — both in London.
In 2009, a cluster-randomized trial showed a 49% reduction in all-cause mortality among Ethiopian children 1 to 9 years of age in the year after mass distribution of a single dose of azithromycin f...
-
Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Charles Hsu, Jason A. Konner, and Mrinal M. Gounder Memorial Sloan Kettering Cancer Center, New York, NY
A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.
-
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22
To the Editor: In the ANNEXA-I trial (Trial of Andexanet Alfa in Intracranial Hemorrhage Patients Receiving an Oral FXa Inhibitor) conducted by Connolly et al. (May 16/23 issue),1 investigators eva...
-
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suarez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross-Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry A. Nosov, Camillo Porta, Jae Lyun Lee
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies.In a phase 3, multicenter, open-label, active-controlled tria...
-
Azithromycin to Reduce Mortality — An Adaptive Cluster-Randomized Trial N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-22 Kieran S. O’Brien, Ahmed M. Arzika, Abdou Amza, Ramatou Maliki, Bawa Aichatou, Ismael Mamane Bello, Diallo Beidi, Nasser Galo, Naser Harouna, Alio M. Karamba, Sani Mahamadou, Moustapha Abarchi, Almou Ibrahim, Elodie Lebas, Brittany Peterson, Zijun Liu, Victoria Le, Emily Colby, Thuy Doan, Jeremy D. Keenan, Catherine E. Oldenburg, Travis C. Porco, Benjamin F. Arnold, and Thomas M. Lietman the AVENIR
Twice-yearly mass distribution of azithromycin to children is a promising intervention to reduce childhood mortality in sub-Saharan Africa. The World Health Organization recommended restricting dis...
-
Preventing and Controlling Global Antimicrobial Resistance — Implementing a Whole-System Approach N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-17 Don Goldmann, Sowmya Rajan, and Krishna Udayakumar From the Duke Global Health Innovation Center, Duke University (D.G., S.R., K.U.), and Innovations in Healthcare (S.R., K.U.) — both in Durham, NC, and the Department of Medicine, Boston Children’s Hospital, the Department of Epidemiology, Harvard T.H. Chan School of Public Health, and the Institute for Healthcare Improvement — all in Boston (D.G.)
Despite efforts to address antimicrobial resistance, many challenges remain, particularly in low- and middle-income countries. Several steps could be taken to accelerate progress.
-
Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-15 Margaret Cupit-Link, and Kohei Hagiwara St. Jude Children’s Research Hospital, Memphis, TN, Matthew Nagy National Cancer Institute, Bethesda, MD, Selene C. Koo, and Brent A. Orr St. Jude Children’s Research Hospital, Memphis, TN, Eytan Ruppin National Cancer Institute, Bethesda, MD, John Easton, Jinghui Zhang, and Sara M. Federico St. Jude Children’s Research Hospital, Memphis, TN , sara.federico@stjude
Some neuroblastomas carry disabling mutations in BARD1, a homologous recombination repair gene. A child with refractory neuroblastoma and a BARD1 mutation had a sustained response after treatment w...
-
Diets N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-15
To the Editor: We suggest expanding the diets that are reviewed by Yannakoulia and Scarmeas (June 13 issue)1 to include the avoidance of foods containing carrageenan, an additive that is used as a ...
-
An Accurate and Rapidly Calibrating Speech Neuroprosthesis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-14 Nicholas S. Card, Maitreyee Wairagkar, Carrina Iacobacci, Xianda Hou, Tyler Singer-Clark, Francis R. Willett, Erin M. Kunz, Chaofei Fan, Maryam Vahdati Nia, Darrel R. Deo, Aparna Srinivasan, Eun Young Choi, Matthew F. Glasser, Leigh R. Hochberg, Jaimie M. Henderson, Kiarash Shahlaie, Sergey D. Stavisky, and David M. Brandman
BACKGROUND Brain–computer interfaces can enable communication for people with paralysis by transforming cortical activity associated with attempted speech into text on a computer screen. Communication with brain–computer interfaces has been restricted by extensive training requirements and limited accuracy. METHODS A 45-year-old man with amyotrophic lateral sclerosis (ALS) with tetraparesis and severe
-
Medical Expertise — Balancing Science, Values, and Trust N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-10 Barron H. Lerner From the Departments of Medicine and Population Health, New York University Grossman School of Medicine, New York.
In an era when physicians’ expertise is widely questioned, rather than assuming that it can be restored with better data, we need to understand how patients process both information and misinformation.
-
In Pursuit of Polka Dots N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-10 Charlotte Hayes From the Department of Neurologic Surgery, Mayo Clinic, Rochester, MN.
Having adapted to her blindness and prosthetic leg, a passionate cyclist confronts the “chronic bonk” of cancer by aiming for the polka-dot jersey that symbolizes the strength to endure.
-
Genital Herpes Zoster N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-10 Chengbei Bao, and Chao Ji First Affiliated Hospital of Fujian Medical University, Fuzhou, China
A 70-year-old man with rheumatoid arthritis presented with painful, red lesions on the right side of his penis and scrotum and on his inner right thigh and a 1-day history of difficulty urinating.
-
Inhibiting IgG in Hemolytic Disease of the Fetus N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-08 Elizabeth G. Phimister, Emeline Maisonneuve, Alice Panchaud, and David Baud From the Materno-fetal and Obstetrics Research Unit, Department “Femme–Mère–Enfant” (E.M., D.B.), and the Service of Pharmacy (A.P.), Lausanne University Hospital and University of Lausanne, Lausanne, and the Institute of Primary Health Care (E.M., A.P.) and the Graduate School for Health Sciences (E.M.), University of Bern
This editorial describes the science behind a study of the monoclonal antibody nipocalimab to postpone or prevent intrauterine transfusion in pregnancies at high risk for early-onset severe hemolyt...
-
Long Covid Defined N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-31 E. Wesley Ely, Lisa M. Brown, and Harvey V. Fineberg the National Academies of Sciences, Engineering, and Medicine Committee on Examining the Working Definition for Long Covid* From the Critical Illness, Brain Dysfunction, and Survivorship Center, Vanderbilt University Medical Center, and the Geriatric Research Education Clinical Center, Veteran’s Affairs, Tennessee Valley — both in Nashville (E.W
Members of the National Academies of Sciences, Engineering, and Medicine describe the process and rationale for the development of the 2024 definition of persistent Covid-19 symptoms (long Covid).
-
From Evidence to Policy — Finding Authoritative Sources of Information on Health N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-31 Eric J. Rubin, and Victor J. Dzau From the National Academy of Medicine, Washington, DC (V.J.D.).
The editors announce a new series of articles representing a collaboration between the National Academy of Medicine and the Journal. The series aims to bring key information from NAM reports to a b...
-
Race-Based Diagnosis, Part 3 N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01
As race-based diagnostic tools, such as pulse oximeters that function poorly on darker skin, continue to lead to inequitable care, a growing movement is working to weed them out of U.S. health care.
-
Galeazzi Fracture N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Wenhai Yan Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
A 47-year-old man presented with right forearm pain after a motorcycle accident. Radiographs showed a distal radius shaft fracture and dislocation of the distal radioulnar joint.
-
Intrathoracic Migration of a Breast Implant N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Dane Stewart, and Laura Thomas University of Kansas School of Medicine, Kansas City, KS
A 73-year-old woman with a history of breast-implant surgery and segmental lung resection had sudden displacement of her right breast implant during pulmonary-function testing.
-
Race-Based Screening under the Public Health Ethics Microscope — The Case of Prostate Cancer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Debra Malina, Camilo Arenas-Gallo, Marsha Michie, Nora Jones, Peter J. Pronovost, and Randy A. Vince From the Departments of Bioethics and Medical Humanities (C.A.-G., M.M.) and Urology (C.A.-G., R.A.V.), University Hospitals Cleveland Medical Center, and the University Hospitals Health System, Case Western University School of Medicine (P.J.P.) — both in Cleveland, and the Center for Urban Bioethics
Principles of public health ethics suggest that committees developing prostate cancer–screening guidelines should thoroughly examine the scientific rationale and social impact of using race-based c...
-
Kidney Disease and Antinephrin Antibodies N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Elizabeth G. Phimister, Jochen Reiser, and Julie R. Ingelfinger From the University of Texas Medical Branch, Galveston (J.R.).
This editorial describes the science behind detecting and treating autoimmunity in kidney disease.
-
A Belantamab Mafodotin Revival in Multiple Myeloma Therapy N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Suzanne Trudel, and A. Keith Stewart From the Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto.
Combination drug regimens that incorporate anti-CD38 monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors, and glucocorticoids are routinely used for the treatment of newly diagnose...
-
Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Elisa Fabbrini Janssen Research and Development, Raritan, NJ, Brian Rady Janssen Research and Development, Spring House, PA, Anastasiya Koshkina, and Jae Yoon Jeon Janssen Research and Development, Raritan, NJ, Vivaswath S. Ayyar, and Cynthia Gargano Janssen Research and Development, Spring House, PA, Nicholas DiProspero, and Susan Wendel Janssen Research and Development, Raritan, NJ, Julia Hegge,
Homozygosity for the PNPLA3 risk allele is linked to liver fat accumulation. In phase 1 trials, JNJ-75220795, a hepatocyte-targeted GalNAc-conjugated PNPLA3 siRNA, reduced liver fat in PNPLA3 I148M...
-
Nirmatrelvir for Adult Outpatients with Covid-19 N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01
To the Editor: We appreciate the contributions of Hammond et al. (April 4 issue) in the evaluation of nirmatrelvir–ritonavir,1 but their current analyses do not capture the whole picture of its eff...
-
Guidance on Energy and Macronutrients across the Life Span N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01
To the Editor: In their review, Heymsfield and Shapses (April 11 issue)1 err in stating that “plant proteins are usually deficient in 1 or more indispensable amino acids.” Although the consumption ...
-
Parkinson’s Disease N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Allan H. Ropper, Caroline M. Tanner, and Jill L. Ostrem From the Movement Disorders and Neuromodulation Center, Department of Neurology, Weill Institute for Neuroscience, University of California, San Francisco, San Francisco.
Parkinson’s disease is a multisystem neurodegenerative disorder with motor and prominent, sometimes premonitory, nonmotor symptoms. Detection of gene variants may inform prognosis and, potentially,...
-
Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease N. Engl. J. Med. (IF 96.2) Pub Date : 2024-08-01 Helen Griffin, Lourdes Ceron-Gutierrez, Nima Gharahdaghi, Soraya Ebrahimi, Sophie Davies, Peh Sun Loo, Andras Szabo, Eleri Williams, Anirban Mukhopadhyay, Louise McLoughlin, Steven Irwin, Simon Travis, Paul Klenerman, Su Bunn, Andrew J. Cant, Sophie Hambleton, Holm H. Uhlig, and Rainer Doffinger From the Immunity and Inflammation Theme, Newcastle University Translational and Clinical Research Institute
We discovered high-titer neutralizing autoantibodies against interleukin-10 in a child with infantile-onset inflammatory bowel disease (IBD), a phenocopy of inborn errors of interleukin-10 signalin...
-
A Tight Squeeze N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-25 Caren G. Solomon, and Bruce D. Levy, John W. Ostrominski, Anand Vaidya, Edwin Mandieka, Victor Kovac, and Arvind K. Pandey
This interactive feature describes a 66-year-old man who presented to the ED with 3 days of progressively worsening chest discomfort. Test your diagnostic and therapeutic skills at NEJM.org.
-
Rape, Homicide, and Abortion Bans — The Abandonment of People Subjected to Sexual and Intimate Partner Violence N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-20 Elizabeth Tobin-Tyler, and Samuel L. Dickman From the School of Public Health and the Warren Alpert Medical School, Brown University, Providence, RI (E.T.-T.), and Planned Parenthood of Montana, Billings (S.L.D.).
Violence against women receives little attention from policymakers and courts. State policymakers who have implemented abortion bans ignore the connections between pregnancy and violence.
-
Chronic Rectal Schistosomiasis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-11 Heullys F. da Silva, and Erb G.C. Monteiro Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil
A 29-year-old man presented with a 2-month history of bright red blood from the rectum. He lived in the interior of northeastern Brazil and regularly bathed in rivers.
-
Adjuvant Pembrolizumab in Renal-Cell Carcinoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-11
To the Editor: Choueiri et al. (April 18 issue)1 report the much-anticipated overall survival results from KEYNOTE-564, a successful trial of adjuvant therapy for patients with high-risk clear-cell...
-
Malnutrition in Adults N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-11 Dan L. Longo, Tommy Cederholm, and Ingvar Bosaeus From Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala (T.C.), Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm (T.C.), Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Stockholm (T.C.), and the Department
Malnutrition occurs in up to 10% of community-dwelling older people and contributes to morbidity and mortality. The two main pathologic pathways are nutrient deprivation and inflammation-induced ti...
-
Funding Postauthorization Vaccine-Safety Science N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-06 Daniel A. Salmon, Walter A. Orenstein, Stanley A. Plotkin, and Robert T. Chen From the Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore (D.A.S.), Emory University, Atlanta (W.O.), the University of Pennsylvania, Philadelphia (S.A.P.), and the Brighton Collaboration, Task Force for Global Health, Decatur, GA (R.T.C.).
The slow speed of science contributes to public concern about vaccines and reduced immunization coverage. Postauthorization safety research requires timely funding linked to the introduction of new...
-
Lipschütz’s Ulcer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-06 Daniela Costa, and Patricia Carvalho Centro de Saude Vila do Conde, Vila do Condo, Portugal
A previously healthy 17-year-old girl presented with a 7-day history of painful genital ulcers. Eight days before the onset of the ulcers, she had had fever, malaise, and a sore throat.
-
Medicare Advantage and Consolidation's New Frontier - The Danger of UnitedHealthcare for All. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-06 Hayden Rooke-Ley,Soleil Shah,Erin C Fuse Brown
-
Four Decades of Orphan Drugs and Priorities for the Future. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-06 Michael S Sinha,Ariel D Stern,Arti K Rai
-
CD7 CAR T-Cell Therapy and Allogeneic HSCT. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-04 Mei Guo,Changlin Yu,Bo Cai
-
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-04 Ignace Vergote,Antonio González-Martín,Keiichi Fujiwara,Elsa Kalbacher,Andrea Bagaméri,Sharad Ghamande,Jung-Yun Lee,Susana Banerjee,Fernando Cotait Maluf,Domenica Lorusso,Kan Yonemori,Els Van Nieuwenhuysen,Luis Manso,Linn Woelber,Anneke Westermann,Allan Covens,Kosei Hasegawa,Byoung-Gie Kim,Miriam Raimondo,Maria Bjurberg,Felipe Melo Cruz,Antoine Angelergues,David Cibula,Lisa Barraclough,Ana Oaknin,Christine
BACKGROUND Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. METHODS We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio
-
Normalization of C1 Inhibitor in a Patient with Hereditary Angioedema. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-04 Nicholas E Peters,Dylan J Mac Lochlainn,Fatima Dhalla,Lucy Howarth,Girish L Gupte,Khalid Sharif,Rashmi Jain,Dominic Kelly,Smita Y Patel
Hereditary angioedema is a potentially life-threatening autosomal dominant condition, causing attacks of angioedema due to failure to regulate bradykinin. Nearly all cases of hereditary angioedema are caused by mutations in the gene encoding C1 inhibitor, SERPING1. C1 inhibitor is a multifunctional protein produced in the liver that regulates the kallikrein-kinin system at multiple points. An infant
-
Acute Abdomen in the Modern Era. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-07-04 Selwyn O Rogers,Orlando C Kirton
-
-
Academic Freedom in America — In Support of Institutional Voices N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-29 Evan Mullen, Eric J. Topol, and Abraham Verghese From the Department of Medicine, Stanford University, Stanford (E.M., A.V.), and the Scripps Research Institute, La Jolla (E.J.T.) — both in California.
Public statements about Covid that a Stanford faculty member made in 2020 reinvigorated debate over academic freedom and institutional obligations, particularly in cases where public health is at s...
-
Downstream - Water Pollution, Health, and Medicine's Duty to Engage. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-29 Shira R Abeles
-
Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-26
Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (N Engl J Med 2003;348:2379-2385). In the Results section of the Abstract (page 2379), the first sentence should ha...
-
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-26 Byoung C. Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, James C.-H. Yang, Michael Thomas, Danny Nguyen, Sai-Hong I. Ou, Sanjay Mukhedkar
Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal g...
-
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Mirna Chehade, Evan S. Dellon, Jonathan M. Spergel, Margaret H. Collins, Marc E. Rothenberg, Robert D. Pesek, Ikuo Hirano, Ruiqi Liu, Elizabeth Laws, Eric Mortensen, Renata Martincova, Arsalan Shabbir, Eilish McCann, Mohamed A. Kamal, Matthew P. Kosloski, Jennifer D. Hamilton, Carin Samuely, Wei Keat Lim, Matthew F. Wipperman, Annamaria Farrell, Naimish Patel, George D. Yancopoulos, Lila Glotfelty
Dupilumab is a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five different atopic diseases marked by type 2 inflammation, including eosi...
-
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Marc E. Rothenberg, Evan S. Dellon, Margaret H. Collins, Albert J. Bredenoord, Ikuo Hirano, Kathryn A. Peterson, Laura Brooks, Julie M. Caldwell, Harald Fjällbrant, Hanna Grindebacke, Calvin N. Ho, Matthew Keith, Christopher McCrae, Dominic Sinibaldi, Wendy I. White, and Catherine J. Datto the MESSINA Trial Investigators* From the Divisions of Allergy and Immunology (M.E.R., J.M.C.) and Pathology and
Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.In a phase 3...
-
Infusion of CARv3-TEAM-E T Cells in Glioblastoma. Reply. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Elizabeth R Gerstner,Bryan D Choi,William T Curry
-
Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Jacob E Møller,Christian Hassager,
-
Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Ing Soo Tiong,David S Ritchie,Piers Blombery
-
Unmasking the Culprits in Eosinophilic Esophagitis Pathogenesis. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Benjamin L Wright
-
Case 20-2024: A 73-Year-Old Man with Recurrent Fever and Liver Lesions. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Lakshmi Ganapathi,Rory L Cochran,Gregory K Robbins,Sara Barmettler,Steven M Holland,Emad I Ababneh
-
Racism, Medicine, and NEJM since 1812 - The Historical Roots of Injustice in Medicine, Symposium 1. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-27 Joan Y Reede,Winfred W Williams,David S Jones,Meghan Bannon Kerr,Scott H Podolsky,Evelynn Hammonds,Joseph P Gone,Merlin Chowkwanyun,Eric J Rubin
-
Entering a New Era in Sleep-Apnea Treatment N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-21 Sanjay R. Patel From the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh.
Obstructive sleep apnea is one of the most common respiratory disorders worldwide. Persons with obstructive sleep apnea can have loud snoring that is detrimental to social relationships and have br...
-
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-21 Atul Malhotra, Ronald R. Grunstein, Ingo Fietze, Terri E. Weaver, Susan Redline, Ali Azarbarzin, Scott A. Sands, Richard J. Schwab, Julia P. Dunn, Sujatro Chakladar, Mathijs C. Bunck, and Josef Bednarik the SURMOUNT-OSA Investigators* From the University of California, San Diego, La Jolla (A.M.), Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University
BACKGROUND Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants
-
State and Local Climate Litigation for Protecting Public Health. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-22 Avery E Emery,Daniel G Aaron
-
Alzheimer's Disease, Biomarkers, and mAbs - What Does Primary Care Need? N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-22 Nathaniel A Chin,Claire M Erickson
-
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-21 Scott R. Plotkin, Kaleb H. Yohay, Phioanh L. Nghiemphu, Christine T. Dinh, Dusica Babovic-Vuksanovic, Vanessa L. Merker, Annette Bakker, Geoffrey Fell, Lorenzo Trippa, and Jaishri O. Blakeley the INTUITT-NF2 Consortium* From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana–Farber Cancer Institute (G.F., L.T.) — all in Boston, the NYU Grossman School of Medicine
NF2-related schwannomatosis (NF2-SWN, formerly called neurofibromatosis type 2) is a tumor predisposition syndrome that is manifested by multiple vestibular schwannomas, nonvestibular schwannomas, ...
-
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma N. Engl. J. Med. (IF 96.2) Pub Date : 2024-06-19 Georgina V. Long, Axel Hauschild, Mario Santinami, John M. Kirkwood, Victoria Atkinson, Mario Mandala, Barbara Merelli, Vanna Chiarion Sileni, Marta Nyakas, Andrew Haydon, Caroline Dutriaux, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, James Larkin, Monique Tan, Sachin Bajirao Adnaik, Paul Burgess, Tarveen Jandoo, and Reinhard Dummer From the
The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis–free survival than placebo among patien...